Gonadotropin-Releasing Hormone

In 1971, GnRH was first isolated from the porcine and ovine by Schally1 and Guillemin, respectively. In nonmammalian vertebrates, GnRH was isolated from the chicken in 1982 and the salmon in 1983. To date, 15 different isoforms of GnRHs have been identified in vertebrates. In nonvertebrate chordates, multiple GnRH-like peptides have been identified in tunicates, first from Chelyosoma productum in 1996.

Vertebrate GnRH isoforms consist of 10 aa residues with a pyroglutamic acid at the N-terminus and an amidated Gly at the C-terminus . Based on the primary structure, phylogenetic analysis, and synteny, multiple GnRH forms are classified into three paralogous groups: GnRH1, GnRH2, and GnRH3.3, 4 The peptides are bent with a β-turn around Gly6 , and the N-terminal and C-terminal amino acid residues are important for binding to the GnRH receptor (GnRH-R).5 Primary structure The primary structure of GnRH is highly conserved in the N-terminus (positions 1–4) and in the C-terminus (positions 9–10). Position 8 is the most variable.

Mr 1050–1250. GnRH is inactivated in 0.9M HCl at 100°C for 60min, and is also inactivated by endopeptidases such as chymotrypsin and papain. mGnRH and cGnRH-I are soluble in water; cGnRH-II and sGnRH are insoluble in water but soluble in 10mM acetic acid.

GnRH-R is a membrane-bound GPCR belonging to the Class A (rhodopsin-like) subfamily. Two major types of GnRH-Rs—type I and type II—have been identified in vertebrates.The type I GnRH-Rs, present in mammals, coelacanth, and some cartilaginous fish, lack a C-terminal intracellular domain that is responsible for rapid desensitization, and show a strong preference for GnRH1. The type II GnRH-Rs, present in both mammalian and nonmammalian species, show a preference for GnRH2. The type II GnRH-Rs are further divided into two subtypes, IIa and IIb. In some mammals, including humans, the type II GnRH-R is a nonfunctional receptor encoded by a pseudogene. The human type I GnRH-R consists of 328 aa residues.

Idiopathic hypogonadotropic hypogonadism (IHH) is a family of genetic disorders that is associated with defects in the production and/or action of hypothalamic peptide, which controls GnRH. As mentioned above, IHH with anosmia is referred to as KS. In addition, the most common cause of delayed puberty is a functional defect in the production of GnRH from the hypothalamus.

The regulation of GnRH secretion by internal and environmental factors such as growth, energy condition, light, photoperiod, temperature, and social status is critical for reproductive success. Regulatory mechanisms of GnRH1 neurons involve many stimulatory and inhibitory factors including gonadal steroids, neuropeptides, and neurotransmitters (GABA, glutamate, norepinephrine). Kisspeptin stimulates GnRH1 secretion and has key roles in the transmission of the negative and positive feedback effects of gonadal steroids, the metabolic regulation, and the photoperiodic control of reproduction. Gonadotrophin-inhibitory hormone (GnIH) may inhibit gonadotropin secretion by decreasing the activity of GnRH1 neurons.

Gonadotropin-releasing hormone is a decapeptide that is produced in neurosecretory cells within the hypothalamus. GnRH stimulates the synthesis and release of luteinizing hormone (LH) and folliclestimulating hormone (FSH) from the anterior pituitary and also controls reproductive behavior, thus serving as a central regulator of reproduction in vertebrates. It is used not only as a fertility drug but also as an antifertility drug.

Oxytocin (Pitocin, Syntocinon) is a cyclic 8–amino acid peptide that is synthesized in the paraventricular nucleus of the hypothalamus and transported within hypothalamic neurons (in association with neurophysin) to the posterior pituitary for storage. Its mechanism of action involves the direct stimulation of oxytocin receptors found on the myometrial cells. Oxytocin circulates unbound in the plasma, where it has a half-life of approximately 15 minutes. It is primarily inactivated in the kidneys and liver.
Oxytocin (Pitocin, Syntocinon) causes milk release (letdown) by stimulating contraction of the myoepithelial cells of the milk ducts in lactating mammary glands; this forces milk from the alveoli of the breast. Oxytocin release is stimulated by suckling and by auditory and visual stimuli, such as a baby’s cry.Oxytocin is available as a nasal spray, which is used as an aid to lactation when milk ejection is impaired.

GnRH (gonadorelin, luteinizing hormone–releasing hormone) is a decapeptide that stimulates production of LH and FSH. It is released in bursts from the hypothalamus at regular intervals, about every 2 hours, although in women the interval may lengthen in the luteal end of the menstrual cycle.The pituitary gland responds to these regular pulses by producing LH and FSH. The pattern of LH and FSH in cycling women, including the large burst of LH release before ovulation, can be stimulated by regular administration of GnRH pulses. The large burst of LH from the pituitary gland appears to be induced by feedback through estradiol and other products of the gonads that change the response of the pituitary gland to the GnRH pulses rather than by large changes in the amounts of GnRH secreted. The stimulatory response to GnRH depends on pulsatile administration and the timing of the pulses. Continual administration of GnRH does not have the same effects as pulsatile administration; although production of LH and FSH is stimulated initially, it is suppressed within a few days. Part of this desensitization to GnRH is caused by a decrease in the number of pituitary receptors for GnRH; additional postreceptor mechanisms are also important in this complete suppression.

ChEBI: Gonadorelin is a ten-membered synthetic oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, glycyl, leucyl, arginyl, prolyl and glycinamide residues joined in sequence. It has a role as a gonadotropin releasing hormone agonist. It is an oligopeptide and a peptide hormone.

Gonadotropin-releasing hormone (GnRH) is a decapeptide that causes the release of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), from the anterior pituitary gland, but not in equal amounts (FSH release is partially inhibited by the gonadal protein inhibin). Therefore, GnRH is intimately involved in the control of both male and female reproduction. Medicinal chemists have capitalized on the relatively simple decapeptide structure of GnRH by preparing many analogues as potential fertility and antifertility agents, several of which are commercially available, especially those that are referred to as superagonists. It is known that GnRH can be degraded by enzymatic cleavage between Tyr5- Gly6 and Pro9-Gly10. Structure–activity relationship studies of GnRH analogues have shown that when Gly6 is replaced with certain D-amino acids, as well as with changes in the peptide C terminus, they generally are less susceptible to proteolytic enzymes, resulting in a longer lasting action. For that reason, they are referred to as superagonists. Furthermore, when these D-amino acids at position 6 are hydrophobic, the half-life is enhanced.

In physiological doses, GnRH agonists are able to induce ovulation and spermatogenesis by increasing LH and FSH levels and the resulting sex steroid levels, as does the normal hormone. In larger pharmacological (therapeutic) doses, however, GnRH agonists, especially the superagonists, block implantation of the fertilized egg, cause luteolysis of the corpus luteum, and can act as postcoital contraceptive agents (although not approved for this latter use). This paradoxical antifertility effect seen with the superagonists has been attributed to the fact that GnRH must be administered in a low-dose, pulsatile manner for it to be therapeutically effective as a fertility agent. Natural GnRH release from the hypothalamus occurs in a pulsatile manner. When GnRH or, especially, a superagonist is administered in pharmacological doses each day, LH and FSH levels will initially rise but then begin to fall after a few days because of target tissue desensitization/downregulation of pituitary GnRH receptors. The continued use of these agents in a nonpulsatile manner will result in a drastic drop of the gonadal steroid levels to near castrate levels in both males and females, thereby giving rise to their use in such conditions as precocious puberty, endometriosis, and advanced metastatic breast and prostate carcinoma.Typically, however, the GnRH superagonists take approximately 2 weeks to finally desensitize the GnRH receptors, and during this time, there is a transient rise in LH and FSH levels, which often results in an initial “flare-up” of the original symptoms.

Because mGnRH has a short half-life of several minutes, a number of GnRH analogs with high potency and long half-life have been synthesized. The effects of GnRH and its analogs are dependent on the dose and method of administration. Low doses of GnRH delivered in a pulsatile fashion restore fertility in hypogonadal patients. High doses of GnRH or continuous administration first results in an increase in LH and FSH secretion, followed by a decrease in LH and FSH levels due to desensitization, then by a decline in gonadal steroid levels. The administration of antagonists interrupts GnRH-dependent LH and FSH secretion through competition with endogenous GnRH, but the doses required are much higher that the desensitizing agonists. mGnRH is available as gonadorelin for veterinary use. Various GnRH agonists are used in the treatment of hormoneresponsive cancers such as prostate and breast cancers, estrogen-dependent conditions such as endometriosis, and precocious puberty. They are also widely used in ART (assisted reproductive technology including IVFET, in vitro fertilization, and embryo transfer) to block the endogenous LH surge in the controlled ovarian stimulation

Oxytocin is generally considered to be the drug of choice for inducing labor at term. In combination with amniotomy, oxytocin is highly successful in inducing and augmenting labor. When given oxytocin, approximately 80% of patients with documented labor disorders progress into labor and deliver vaginally. It has also been used following incomplete abortion after 20 weeks of gestation (although use of prostaglandins may be preferred in this instance), and it may be used after fullterm delivery to prevent or control uterine hemorrhage. Oxytocin in high doses is used to induce abortion. An oxytocin challenge test (an assessment of the fetal heart rate in response to oxytocin-induced contractions) can be performed in certain high-risk (e.g., those with hypertension, diabetes, preeclampsia) obstetrical patients as a measure of fetal well-being.

Inappropriate use of oxytocin can lead to uterine rupture, anaphylactoid and other allergic reactions, and possibly maternal death. Prolonged stimulation of uterine contractions can result in the following fetal adverse reactions: persistent uteroplacental insufficiency, sinus bradycardia, premature ventricular contractions, other arrhythmias, and fetal death. Prolonged use of oxytocin can lead to water intoxication secondary to the antidiuretic hormone–like effects of oxytocin. Maternal and fetal cardiovascular parameters should be monitored during oxytocin administration.

An experimental teratogen. Human reproductive effects in women by subcutaneous route: menstrual cycle changes and other unspecified effects. Experimental reproductive effects. Used in the treatment of oligospermia and male inferthty. See also LUTEINIZING HORMONE and other luteinizing hormone-releasing hormone entries.